How much is ocugen stock worth?
Apr 15, 2022 · Ocugen's stock is owned by a number of institutional and retail investors. Top institutional investors include Cutler Group LP (0.00%) and Dynamic Advisor Solutions LLC (0.02%). Company insiders that own Ocugen stock include Christopher Dold, Daniel Purefoy, Junge Zhang , Kirsten Castillo , Manish Potti , Prabhavathi Fernandes , Ramesh Kumar , Sanjay …
What does ocugen do?
Apr 18, 2022 · Why Ocugen Stock Flopped Then Popped Today. Why Ocugen Stock Is Jumping Today. 1 Green Flag for Ocugen in 2022, and 1 Red Flag. 4 Numbers That Make Ocugen an Extremely Risky Buy.
Is ocgn (ocgn) stock a good value?
Apr 14, 2022 · OCGN Ocugen — Stock Price and Discussion | Stocktwits. Ocugen NASDAQ Updated Apr 14, 2022 11:56 PM. OCGN 2.76 0.21 (7.07%) Post-Market 0.05 (1.81%) 154,497. Key Data. 52wk Low 2.16. 52wk High 17.65.
What are ocugen's price targets for the next 12 months?
Apr 19, 2022 · Apr. 18, 2022, 07:25 PM. Although it had good news to report, Ocugen (NASDAQ: OCGN) nevertheless saw its stock decline by almost 6% on Monday. That news clearly wasn't good enough for investors ...
Is Ocugen a good stock?
Ocugen is a dangerous investment, especially given it is unprofitable, it's burning through money, and investors have been wary of growth stocks of late. Unless you're prepared for the risk, you're better off avoiding Ocugen.Feb 25, 2022
What can I expect from Ocugen stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +137.69% increase from the last price of 2.95.
Is Ocugen a buy or sell?
Ocugen has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
What does Ocugen Inc do?
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
Will Ocugen go up?
Long-term Ocugen stock forecast 2022-2025 The site predicted that the share price could climb over the next year, to $7.2 by March 2023.
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.97, with a high estimate of 86.67 and a low estimate of 24.11. The median estimate represents a +71.83% increase from the last price of 19.19.
Will Ocugen stock go up tomorrow?
Tomorrow's movement Prediction of Ocugen Inc OCGN as on 04 Apr 2022 appears strongly Bullish. This stock started moving upwards as soon as it opened....Munafa value: 65 as on 04 Mon Apr 2022.Upside target3.75Upside target3.47Downside target3.33Downside target3.3Downside target3.185 more rows
Why is Ocugen stock so low?
What happened. Shares of Ocugen ( OCGN -7.07% ) were crashing 19.2% lower as of 11:23 a.m. ET on Friday. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18.Mar 4, 2022
Is Ocugen publicly traded?
Yes, Ocugen Inc is a publicly traded company.
Did Ocugen get FDA approved?
The FDA has denied Ocugen's Emergency Use Authorization (EUA) request for use of its COVID-19 vaccine in children aged two to 18 years.Mar 7, 2022
How effective is Ocugen vaccine?
Results showed an efficacy rate of 65.2% (95% CI; 33.1-83.0). Adverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events, side effects that keep many from considering taking current vaccines.Jul 2, 2021
Who is making Covaxin?
COVAXIN®, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
Is Ocugen a buy right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 3 hold ratings and 2...
How has Ocugen's stock been impacted by Coronavirus (COVID-19)?
Ocugen's stock was trading at $0.3612 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organiz...
When is Ocugen's next earnings date?
Ocugen is scheduled to release its next quarterly earnings announcement on Friday, May 6th 2022. View our earnings forecast for Ocugen .
How were Ocugen's earnings last quarter?
Ocugen, Inc. (NASDAQ:OCGN) posted its quarterly earnings data on Friday, February, 25th. The company reported ($0.07) EPS for the quarter, meeting...
What price target have analysts set for OCGN?
5 analysts have issued 1-year price targets for Ocugen's shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate Ocugen's s...
Who are Ocugen's key executives?
Ocugen's management team includes the following people: Shankar Musunuri , Chairman & Chief Executive Officer ( LinkedIn Profile ) Sanjay Subram...
Who are some of Ocugen's key competitors?
Some companies that are related to Ocugen include ImmunityBio (IBRX) , Bavarian Nordic A/S (BVNRY) , Twist Bioscience (TWST) , Iovance Biothera...
What other stocks do shareholders of Ocugen own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX)...
What is Ocugen's stock symbol?
Ocugen trades on the NASDAQ under the ticker symbol "OCGN."
About Ocugen
Headlines
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN.
Ocugen (NASDAQ:OCGN) Frequently Asked Questions
Ocugen shares are trading lower after the company announced a proposed public offering of common stock. - Benzinga
Key Points
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ocugen stock.
NASDAQ: OCGN
Ocugen's COVID-19 vaccine has a clear path forward now that the FDA has lifted a clinical hold.
The company's shares jumped on positive news from the FDA
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
A 3-month hold
Ocugen ( OCGN -2.40% ) got some positive news last week as the Food and Drug Administration (FDA) lifted the clinical hold on its investigational new drug application (IND) for Covaxin, also known as BBV152. The stock jumped in after-hours trading on the news, though it has since dropped.
NASDAQ: OCGN
On Nov. 26, Ocugen released a statement saying that the FDA had issued a clinical hold on its IND for Covaxin, a COVID-19 vaccine it is co-developing with India-based Bharat Biotech. It said the agency was going to "identify the specific deficiencies that are the basis for clinical hold and information on how to address those deficiencies."
The path is clear, but is approval imminent?
There wasn't any indication then, nor is there now, as to how serious the deficiencies were. Nonetheless, they were sufficient to stall the IND.
The stock remains ultra-risky
The World Health Organization (WHO) has issued an emergency use listing for Covaxin, and the vaccine is approved for use in 13 countries.
